# Atea Pharmaceuticals, Inc. Common Stock (AVIR)

> Atea Pharmaceuticals, Inc. Common Stock (AVIR) trades at $3.96 (+0.76%) as of 4:10:03 PM EST on Nov 20, 2026, -2.22% over the past month. Market cap is $315.6M, with 9.6 days to cover in short interest.

Canonical: https://massive.com/quote/avir
Data as of: 2026-11-20T21:10:03.840Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$3.96** +0.03 (+0.76%)
As of 4:10:03 PM EST on Nov 20, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Atea Pharmaceuticals, Inc. Common Stock (AVIR) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.76% |
| 1W | -7.91% |
| 1M | -2.22% |
| YTD | +10.92% |
| 1Y | +33.33% |
| 52-wk range | $2.93 – $6.45 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for AVIR: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $3.80 – $4.09 |
| Open | $3.88 |
| Prev close | $3.93 |
| Volume | 416.46K |
| Market cap | $315.6M |
| Shares out | 80.3M |

## Valuation and profitability ratios

Valuation and profitability ratios for Atea Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.80 |
| P/FCF | — |
| ROE | -88.5% |
| ROA | -77.4% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 19, 2026

## Insider trading

[Atea Pharmaceuticals, Inc. Common Stock (AVIR) insider trading](https://massive.com/quote/avir/insider-trading.md): open-market Form 4 buys and sells by Atea Pharmaceuticals, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Atea Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 9, 2026, Atea Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended September 30, 2026.”
- Nov 9, 2026 · Credit facility
  “On November 6, 2026 (the "Closing Date"), Atea Pharmaceuticals, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc., as agent, and the lenders party thereto, providing for term loans in an aggregate principal amount of up to $200.0 million. The Agreement provides for senior secured term loans maturing on November 1, 2031.”
- Jan 8, 2026 · [Preliminary results](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On January 8, 2026, Atea Pharmaceuticals, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited cash and investment balance as of December 31, 2025.”
- Jun 20, 2025 · Annual meeting results
  “On June 20, 2025, Atea Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders. Based upon the foregoing votes, Bruno Lucidi, Dr. Polly Murphy and Dr. Bruce Polsky were elected as Class II directors and Proposals 2 and 3 were approved.”
- Apr 17, 2025 · Director departure
  “Franklin Berger will not stand for reelection to the Board as a Class I director when his term expires at the Company's 2027 annual meeting of stockholders. Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.”

## Dividend history and stock splits

Atea Pharmaceuticals, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-11 · Feb 14, 2018

## AVIR short interest

How heavily AVIR is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 9.6 |
| Short interest | 3.01M |
| Avg volume | 315.09K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## AVIR news

The latest news and headlines about Atea Pharmaceuticals, Inc. Common Stock (AVIR).

- [Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026](https://www.globenewswire.com/news-release/2026/05/27/3301752/0/en/Atea-Pharmaceuticals-Presents-New-Drug-Drug-Interaction-Results-Supporting-Potential-Best-in-Class-Profile-of-the-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-the-Treatment-of-Hepatit.html) · GlobeNewswire Inc. · May 27, 2026 · positive sentiment
- [Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026](https://www.globenewswire.com/news-release/2026/02/24/3243336/0/en/Atea-Pharmaceuticals-Presents-Preclinical-Results-Supporting-First-in-Class-Potential-of-AT-587-for-Treatment-of-Hepatitis-E-Virus-at-CROI-2026.html) · GlobeNewswire Inc. · Feb 24, 2026 · positive sentiment
- [Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025](https://www.globenewswire.com/news-release/2025/11/07/3183594/0/en/Atea-Pharmaceuticals-Presents-New-Data-Supporting-the-Fixed-Dose-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-a-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-I.html) · GlobeNewswire Inc. · Nov 7, 2025 · positive sentiment
- [Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025](https://www.globenewswire.com/news-release/2025/11/05/3181255/0/en/Atea-Pharmaceuticals-to-Host-Third-Quarter-2025-Financial-Results-and-Business-Update-Conference-Call-on-November-12-2025.html) · GlobeNewswire Inc. · Nov 5, 2025 · neutral sentiment
- [Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025](https://www.globenewswire.com/news-release/2025/07/31/3124832/0/en/Atea-Pharmaceuticals-to-Host-Second-Quarter-2025-Financial-Results-and-Business-Update-Conference-Call-on-August-7-2025.html) · GlobeNewswire Inc. · Jul 31, 2025 · neutral sentiment

## About Atea Pharmaceuticals, Inc. Common Stock

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Listed | Oct 30, 2020 |

[Company website](https://www.ateapharma.com)

## FAQ

### What is the Atea Pharmaceuticals, Inc. Common Stock (AVIR) stock price today?

Atea Pharmaceuticals, Inc. Common Stock (AVIR) is trading at $3.96 (+0.76% on the day) as of 4:10:03 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Atea Pharmaceuticals, Inc. Common Stock?

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases.

### What is the short interest in AVIR?

As of Oct 30, 2026, AVIR has 3.01M shares short and 9.6 days to cover.

### What exchange is AVIR listed on?

Atea Pharmaceuticals, Inc. Common Stock (AVIR) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time AVIR quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AVIR`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Atea Pharmaceuticals, Inc. Common Stock (AVIR) insider trading](https://massive.com/quote/avir/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
